Saracatinib identified as potential FOP treatment

Experimental data suggest that the tyrosine kinase inhibitor saracatinib may be a candidate for the treatment of fibrodysplasia ossificans progressiva (FOP), via its inhibition of activin receptor-like kinase (ALK)2.

FOP great toe shows two developmental phenotypes

A detailed analysis of radiographs from individuals with ACVR1R206H -mutated fibrodysplasia ossificans progressiva (FOP) has found that great toe malformations result from monophalangeal and biphalangeal phenotypes.